| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 2,798 | 2,651 | 3,230 | 2,708 | 2,843.99 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,798 | 2,651 | 3,230 | 2,708 | 2,843.99 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 83 | 122 | 20 | 1,476 | 184.17 |
Total Income | 2,881 | 2,773 | 3,250 | 4,184 | 3,028.16 |
Total Expenditure | 2,773 | 2,844 | 3,115 | 2,773 | 2,724.96 |
PBIDT | 108 | -71 | 135 | 1,411 | 303.2 |
Interest | 305 | 302 | 299 | 249 | 275.74 |
PBDT | -197 | -373 | -164 | 1,162 | 27.46 |
Depreciation | 223 | 251 | 247 | 246 | 224.14 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 16 | 12 | 38 | 192 | 6.07 |
Deferred Tax | 36 | -15 | -170 | 36 | -159.36 |
Reported Profit After Tax | -472 | -621 | -279 | 688 | -43.39 |
Minority Interest After NP | -9 | -62 | -35 | 2 | 25.83 |
Net Profit after Minority Interest | -463 | -559 | -244 | 686 | -69.22 |
Extra-ordinary Items | -57.83 | -288.35 | -166.08 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | -405.17 | -270.65 | -77.92 | 686 | -69.22 |
EPS (Unit Curr.) | -32.05 | -38.79 | -20.24 | 61.95 | -6.25 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 77 | 72 | 72 | 55.39 | 55.37 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 3.85 | -2.67 | 4.17 | 52.1 | 10.66 |
PBDTM(%) | -7.04 | -14.07 | -5.07 | 42.9 | 0.96 |
PATM(%) | -16.86 | -23.42 | -8.63 | 25.4 | -1.52 |
WCK 6777 is the only once-a-day antibiotic in the global pipeline designated for outpatient parenteral antimicrobial therapy (OPAT).
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
